Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain

NCT ID: NCT01752322

Last Updated: 2016-07-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

444 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Chronic Pain Neuropathic Pain Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lidocaine plaster

Topical hydrogel plaster

Group Type EXPERIMENTAL

Lidocaine 5% medicated plaster

Intervention Type DRUG

Placebo plaster

Topical hydrogel plaster

Group Type PLACEBO_COMPARATOR

Placebo plaster

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine 5% medicated plaster

Intervention Type DRUG

Placebo plaster

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects aged 18 years or older.
* Subjects suffering from moderate to severe localized chronic PoNP (post operative neuropathic pain) pain following surgery (e.g., thoracotomy, total/partial knee replacement, cholecystectomy, mastectomy, inguinal hernia repair, varicose vein stripping).
* Localized PoNP present for at least 3 months.
* Size of the affected painful skin area is not larger than the size of 3 plasters.
* Intact skin besides the scar of surgery in the area of plasters application
* Baseline average pain intensity of 4 or greater on the 11 point pain intensity Numeric Rating Scale.

Exclusion Criteria

* Participation in another trial (with medicine or a device under investigation) in parallel or less than 30 days prior to enrollment in this trial.
* Previous enrollment in this trial.
* History of dependency or active drug abuse (alcohol, medication) during the 1 year prior to enrollment.
* Evidence or history (during the 3 years prior to enrollment) of neurotic personality or psychiatric illness that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subjects safety during trial participation.
* Pregnant or breastfeeding women or women of childbearing potential who are sexually active without satisfactory contraception.
* Any surgery performed in the 3 months prior to enrollment, which may affect efficacy or safety assessment.
* Any surgery scheduled or expected during the trial.
* Clinically significant disease (e.g., acquired immunodeficiency syndrome) or condition that may affect efficacy or safety assessments, or any other reason which, in investigator's opinion, may preclude the subject's participation in the trial.
* History of malignancy (with the exception of neoplasia related to the trial indication) within 2 years prior to enrollment.
* Subject with PoNP related to a surgery due to neoplasia: suspected residual neoplasia or metastases.
* Pending litigation due to chronic pain or disability.
* Total anesthesia in the cutaneous area neurologically related to the location of the surgical intervention.
* Hypersensitivity to the lidocaine 5% medicated plaster, its excipients, or anesthetics of the amide type.
* Any former use of topical lidocaine in the area of localized chronic PoNP.
* Severe renal, hepatic or heart disorder.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Grünenthal GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Grünenthal GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AUT004

Klagenfurt, , Austria

Site Status

AUT005

Senftenberg, , Austria

Site Status

AUT001

Vienna, , Austria

Site Status

AUT006

Vienna, , Austria

Site Status

AUT002

Vienna, , Austria

Site Status

AUT003

Vienna, , Austria

Site Status

BEL001

Gozée, , Belgium

Site Status

BEL006

Halen, , Belgium

Site Status

BEL004

Ham, , Belgium

Site Status

BEL007

Lanaken, , Belgium

Site Status

BEL002

Natoye, , Belgium

Site Status

BRA005

Barretos, , Brazil

Site Status

BRA002

Itajaí, , Brazil

Site Status

BRA001

Porto Alegre, , Brazil

Site Status

BR008

Salvador, , Brazil

Site Status

BRA003

São Paulo, , Brazil

Site Status

BRA006

São Paulo, , Brazil

Site Status

BRA007

São Paulo, , Brazil

Site Status

DNK005

Copenhagen, , Denmark

Site Status

DNK004

Glostrup Municipality, , Denmark

Site Status

DNK001

Odense, , Denmark

Site Status

FRA004

Amiens, , France

Site Status

FRA002

Bordeaux, , France

Site Status

FRA001

Boulogne-Billancourt, , France

Site Status

FRA003

Le Chesnay, , France

Site Status

FRA005

Lille, , France

Site Status

FRA010

Montauban, , France

Site Status

FRA006

Nantes, , France

Site Status

FRA009

Paris, , France

Site Status

FRA008

Saint-Priest-en-Jarez, , France

Site Status

FR007

Toulouse, , France

Site Status

ITA004

Florence, , Italy

Site Status

ITA003

Napoli, , Italy

Site Status

ITA001

Rome, , Italy

Site Status

ESP001

Barcelona, , Spain

Site Status

ESP002

Barcelona, , Spain

Site Status

ESP006

Madrid, , Spain

Site Status

ESP005

Madrid, , Spain

Site Status

GBR003

Cardiff, , United Kingdom

Site Status

GBR001

Glasgow, , United Kingdom

Site Status

GBR004

Liverpool, , United Kingdom

Site Status

GBR002

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Brazil Denmark France Italy Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Palladini M, Boesl I, Koenig S, Buchheister B, Attal N. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial. Curr Med Res Opin. 2019 May;35(5):757-766. doi: 10.1080/03007995.2019.1565709. Epub 2019 Jan 21.

Reference Type DERIVED
PMID: 30614286 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-000347-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

KF10004/10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topical Lidocaine Patch in Low Back Pain
NCT00904540 COMPLETED PHASE4
ACD440 Gel in Peripheral Neuropathic Pain
NCT05416931 COMPLETED PHASE2
Neuromas as the Cause of Pain
NCT02930551 COMPLETED NA